As the phosphorylation of Akt can induce the resistance of breast cancer to trastuzumab treatment (31,32), the results of the current study indicate that the treatment of HER2-positive tumors with pAkt inhibitors may aid in overcoming trastuzumab resistance. The gene discussed is ERBB2; the disease is breast cancer.